Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients

Non-small Cell Lung Cancer Clinical Trial

Official title:

A Prospective, Open-label, Single-arm, Phase II Trial Investigating the Efficacy and Safety of Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05758116
• Other study ID #: 2022YJZ46
• Status: Recruiting
• Phase: Phase 2
• Start date: July 7, 2022
• Est. completion date: July 7, 2026

Study information

• Verified date: March 2023
• Source: Peking University Cancer Hospital & Institute
• Contact: Rong Yu, MD
• Phone: 13501147200
• Email: yurong311[@]aliyun.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The current standard of care for locally advanced non-small cell lung cancer (NSCLC) is concurrent chemoradiation and consolidation immunotherapy. In real world clinical practice, patients who cannot tolerate concurrent chemoradiation generally received radiotherapy alone or sequential chemoradiation. These patients are more likely to develop distant metastases and therefore may require tolerable systemic consolidation regimens. However, there is a lack of evidence from clinical studies on consolidation immunotherapy after radiotherapy alone or sequential chemoradiation. The aim of the study is to explore the efficacy and safety of Tislelizumab consolidation therapy after radiotherapy or sequential chemoradiation in locally advanced NSCLC patients who are intolerable of concurrent concurrent chemoradiation.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: July 7, 2026
• Est. primary completion date: July 7, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients with stage III(AJCC 8th) unresectable NSCLC, or resectable but intolerant or refusing surgery;

2. Intolerable of concurrent chemoradiation;

3. No progression after radiotherapy or sequential chemoradiation;

4. Chemotherapy: standard dose of 2-6 cycles of paclitaxel, pemetrexed or gemcitabine in combination with platinum; Radiotherapy: starting within 3 months after chemotherapy using IMRT or VMAT technique. The target volume includes the primary tumor and regional lymph nodes, and the prescription dose 95% PTV ranges from 50Gy to 66Gy;

5. ECOG PS0-2;

6. PD-L1=1%;

7. Age=18 years, and life expectancy>3 months;

8. Adequate Hematologic, biochemistry and organ function (to be confirmed by test results within 7 days prior to the first dose);

9. Be able to provide written informed consent (ICF) and able to understand and agree to comply with study requirements and assessment schedule.

Exclusion Criteria:

1. Patients with EGFR-sensitive mutations and ALK rearrangements;

2. Any prior use of anti-PD-1, anti-PD-L1, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibodies (including Ipilimumab or any other antibody targeting the T-cell co-stimulation or checkpoint pathway);

3. History of allergy to components of Tislelizumab;

4. Any active malignancy within 2 years prior to enrollment, except for the specific cancers examined in this study and any locally recurrent cancers that have been eradicated (e.g., resected basal or squamous cell skin cancer, superficial bladder cancer, cervical or breast cancer in situ);

5. History of interstitial lung disease or pneumonia requiring oral or intravenous steroids;

6. Progression after radiotherapy or sequential chemoradiation;

7. Unresolved =grade2 toxicities from radiotherapy and sequential chemoradiation, (excluding those that the investigator determines do not affect study treatment, such as alopecia);

8. Grade 2 or severe Pneumonia from radiotherapy or sequential chemoradiation;

9. Administration of a live vaccine within 30 days prior to treatment start (seasonal influenza vaccine without live vaccine is allowed);

10. Severe chronic or active infections (including tuberculosis infections, etc.) requiring systemic antibacterial, antifungal or antiviral therapy = 14 days prior to treatment start;

11. History of immunodeficiency, including a positive HIV test, or other acquired or congenital immunodeficiency disease, or a history of organ transplantation;

12. History of active autoimmune disease requiring systemic therapy;

13. Treatment with long-term systemic immunosuppressive medications (=10 mg/d prednisone or equivalent doses of other steroids) or other immunosuppressive medications;

14. History of uncontrolled cardiovascular disease; or clinically significant QT interval prolongation, or QTc interval >480 ms during screening period;

15. Abnormal liver function [total bilirubin > 1.5 times of the upper limit of normal value; ALT/AST > 2.5 times of the upper limit of normal value in patients without liver metastases and ALT/AST > 5 times of the upper limit of normal value in patients with liver metastases], abnormal renal function (serum creatinine > 1.5 times of the upper limit of normal value);

16. History of serious concomitant diseases (e.g., severe hypertension, diabetes, thyroid disease, active infection, etc.) ;

17. History of diagnosed neurological or psychiatric disorders, including epilepsy or dementia;

18. Unsuitable for participation in this study assessed by investigators;

19. Patients who were already enrolled in other clinical studies;

20. Mixed lung cancer with small cell components.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Non-small Cell Lung Cancer

Intervention

Drug:
• Tislelizumab
Tislelizumab: 200mg d1,q21d*17

Locations

Country	Name	City	State
China	Peking University Cancer Hospital and Institute	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Peking University Cancer Hospital & Institute

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free survival	Defined from the date of enrollment to the date of death or any recurrence.	6 months after enrollment
Secondary	Overall survival	Defined from the date of enrollment to the date of death.	From date of enrollment to maximum of 3 years or death
Secondary	Objective response rate	Defined as the occurrence of a complete or partial response per RECIST 1.1 criteria.	From date of enrollment to maximum of 3 years or death
Secondary	Treatment-related adverse events	Graded according to NCI-CTCAE v5.0	Duration of treatment and follow up until death or 3 years after enrollment